​
​

Ligand Pharmaceuticals (LGND) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Ligand Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$131.31M

Latest Revenue (Q)

$51.81M

Main Segment (Y)

Material Sales, Captisol

Ligand Pharmaceuticals Revenue by Period

Ligand Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$131.31M-33.09%
2022-12-31$196.25M-29.19%
2021-12-31$277.13M48.66%
2020-12-31$186.42M54.98%
2019-12-31$120.28M-52.17%
2018-12-31$251.45M78.21%
2017-12-31$141.10M29.48%
2016-12-31$108.97M51.53%
2015-12-31$71.91M11.43%
2014-12-31$64.54M31.78%
2013-12-31$48.97M56.03%
2012-12-31$31.39M4.50%
2011-12-31$30.04M27.61%
2010-12-31$23.54M-39.55%
2009-12-31$38.94M42.56%
2008-12-31$27.32M111.84%
2007-12-31$12.89M-90.85%
2006-12-31$140.96M-20.18%
2005-12-31$176.61M8.01%
2004-12-31$163.51M15.85%
2003-12-31$141.14M46.05%
2002-12-31$96.64M26.59%
2001-12-31$76.34M58.68%
2000-12-31$48.11M17.63%
1999-12-31$40.90M131.07%
1998-12-31$17.70M-65.76%
1997-12-31$51.70M40.49%
1996-12-31$36.80M50.20%
1995-12-31$24.50M84.21%
1994-12-31$13.30M-

Ligand Pharmaceuticals generated $131.31M in revenue during NA 2023, up -33.09% compared to the previous quarter, and up 52.22% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$51.81M24.76%
2024-06-30$41.53M34.07%
2024-03-31$30.98M10.24%
2023-12-31$28.10M-14.50%
2023-09-30$32.87M24.66%
2023-06-30$26.37M-40.05%
2023-03-31$43.98M-12.71%
2022-12-31$50.38M-23.77%
2022-09-30$66.09M15.10%
2022-06-30$57.42M25.66%
2022-03-31$45.69M-36.95%
2021-12-31$72.47M11.78%
2021-09-30$64.83M-23.43%
2021-06-30$84.67M53.54%
2021-03-31$55.15M-21.20%
2020-12-31$69.99M67.25%
2020-09-30$41.85M1.03%
2020-06-30$41.42M24.91%
2020-03-31$33.16M22.80%
2019-12-31$27.00M8.85%
2019-09-30$24.81M-0.72%
2019-06-30$24.99M-42.54%
2019-03-31$43.48M-27.03%
2018-12-31$59.59M30.50%
2018-09-30$45.66M-49.29%
2018-06-30$90.04M60.34%
2018-03-31$56.16M11.28%
2017-12-31$50.46M51.20%
2017-09-30$33.38M19.22%
2017-06-30$28.00M-4.35%
2017-03-31$29.27M-23.35%
2016-12-31$38.19M76.63%
2016-09-30$21.62M10.75%
2016-06-30$19.52M-34.16%
2016-03-31$29.65M39.90%
2015-12-31$21.19M19.72%
2015-09-30$17.70M-3.89%
2015-06-30$18.42M26.13%
2015-03-31$14.60M-36.51%
2014-12-31$23.00M53.60%
2014-09-30$14.97M41.15%
2014-06-30$10.61M-33.53%
2014-03-31$15.96M8.29%
2013-12-31$14.74M13.32%
2013-09-30$13.01M35.75%
2013-06-30$9.58M-17.78%
2013-03-31$11.65M-14.55%
2012-12-31$13.63M113.88%
2012-09-30$6.38M11.02%
2012-06-30$5.74M1.88%
2012-03-31$5.64M-56.43%
2011-12-31$12.94M125.33%
2011-09-30$5.74M-23.07%
2011-06-30$7.46M91.56%
2011-03-31$3.90M-1.12%
2010-12-31$3.94M-49.50%
2010-09-30$7.80M33.64%
2010-06-30$5.84M-2.01%
2010-03-31$5.96M-57.37%
2009-12-31$13.98M76.90%
2009-09-30$7.90M4.04%
2009-06-30$7.59M-19.81%
2009-03-31$9.47M-23.56%
2008-12-31$12.39M136.07%
2008-09-30$5.25M9.24%
2008-06-30$4.80M-1.44%
2008-03-31$4.87M-15.53%
2007-12-31$5.77M-

Ligand Pharmaceuticals generated $51.81M in revenue during Q3 2024, up 24.76% compared to the previous quarter, and up 196.51% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue Breakdown

Ligand Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Material Sales, Captisol, COVID$88.07M----
Material Sales, Captisol$104.50M$164.25M$109.96M$31.49M$29.12M
License Fees, Milestones, and Other Product, Other$6.11M$6.41M$4.97M$12.17M$9.00M
License Fees$2.85M$5.08M$4.38M$6.20M$78.19M
Contract Revenue$19.22M$63.96M$42.66M--
Service$1.12M$23.71M$21.80M--
Royalty, Other$7.63M$11.38M$2.57M--
Royalty, Kyprolis$30.12M$27.47M$25.05M--
Royalty, Evomela$10.20M$10.08M$5.17M--
Royalty$72.53M$48.93M$46.98M--
Milestone$9.15M$28.75M$11.52M$23.45M$6.58M
Material Sales, Captisol, Core$16.43M----
Royalty, Promacta---$14.19M-
License Fees, Milestones, and Product, Other---$41.82M$93.77M

Ligand Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Material Sales, Captisol (28.40%), Material Sales, Captisol, COVID (23.94%), Royalty (19.71%), Royalty, Kyprolis (8.19%), Contract Revenue (5.22%), Material Sales, Captisol, Core (4.47%), Royalty, Evomela (2.77%), Milestone (2.49%), Royalty, Other (2.07%), License Fees, Milestones, and Other Product, Other (1.66%), License Fees (0.77%), and Service (0.30%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Sep 19Jun 19Mar 19Sep 18Jun 18Mar 18
Teriparatide Injection$2.38M$3.61M$3.50M$4.07M$5.50M$2.91M-------------
Rylaze$3.89M$3.03M$2.61M$2.10M$2.32M$1.65M-------------
Royalty, Other$2.27M$3.33M$2.27M$3.78M$1.42M$619.00K$1.81M$4.16M$983.00K$492.00K$280.00K$501.00K$584.00K------
Royalty$31.71M$20.43M$17.15M$21.04M$19.84M$17.96M$13.70M$15.65M$8.62M$7.11M$9.01M$7.18M$6.57M$20.80M-----
Material Sales, Captisol$6.25M$5.22M$10.62M$26.88M$35.95M$29.55M$12.12M$35.09M$62.51M$31.27M$23.39M$7.61M$4.39M------
Kyprolis$11.60M$8.10M$6.23M$9.12M$7.13M$4.62M$8.82M$5.44M$4.29M$6.92M$5.48M$4.41M-------
Intangible Royalty Assets$26.55M------------------
Financial Royalty Assets$5.16M------------------
Evomela$1.75M$2.36M$2.55M$3.12M$2.39M$2.70M$2.67M$2.19M$2.33M$1.80M$1.20M$1.58M-------
Contract Revenue-$716.00K$16.20M$-20.87M$10.30M$9.91M$19.88M$14.09M$13.55M$16.77M$9.45M$5.19M$2.13M------
License Fees-$508.00K$114.00K$-2.31M$460.00K$1.61M$3.09M$200.00K$1.05M$1.04M$158.00K$47.98M$26.95M------
License Fees, Milestones, and Product, Other, Product, Other-$208.00K$789.00K$1.21M$1.58M$2.56M$1.65M$1.54M$1.84M$995.00K$1.14M$1.17M-------
Material Sales, Captisol, COVID---$23.58M$32.37M$26.22M$5.90M------------
Material Sales, Captisol, Core-$5.22M$10.62M$3.30M$3.58M$3.33M$6.23M------------
Milestone--$15.30M$-4.87M$3.66M$1.27M$9.09M$7.42M$3.60M$8.42M$960.00K$1.92M$2.83M------
Contract Revenue, Service----$4.97M$5.45M$5.15M$4.83M$7.36M$5.46M$7.34M--------
Promacta---------------$14.19M---
Service-----------$4.58M$3.36M------
MilestoneMember-----------$3.47M$334.00K------
MaterialSalesCaptisolMember-----------$24.47M$21.11M$7.03M-----
LicenseFeesMilestonesandProductOtherProductOtherMember-----------$1.06M$821.00K------
LicenseFeesMember-----------$660.00K$975.00K------
LicenseFeesMilestonesandProductOtherMember----------------$2.51M--
License Fees, Milestones, and Product, Other-----------------$51.03M$30.95M
Royalty, Evomela------------------$1.60M
Royalty, Kyprolis------------------$3.30M
Royalty, Product, Other------------------$400.00K
Royalty, Promacta------------------$15.60M

Ligand Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Royalty (34.63%), Intangible Royalty Assets (29.00%), Kyprolis (12.67%), Material Sales, Captisol (6.83%), Financial Royalty Assets (5.63%), Rylaze (4.24%), Teriparatide Injection (2.60%), Royalty, Other (2.48%), and Evomela (1.91%).

Ligand Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BGNEBeiGene$2.46B$929.17M
APLSApellis Pharmaceuticals$366.28M$176.57M
ASNDAscendis Pharma$266.72M$95.89M
BPMCBlueprint Medicines$249.38M$128.18M
LGNDLigand Pharmaceuticals$131.31M$51.81M
RCUSArcus Biosciences$117.00M$48.00M
RLAYRelay Therapeutics$25.55M-
CYTKCytokinetics$7.53M$463.00K
CRNXCrinetics Pharmaceuticals$4.01M-
VRDNViridian Therapeutics$314.00K$86.00K
LYELLyell Immunopharma$130.00K$34.00K
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
GPCRStructure Therapeutics--
ANNXAnnexon--
PASGPassage Bio--
TERNTerns Pharmaceuticals--
ETNB89bio--
ORICORIC Pharmaceuticals--
AKROAkero Therapeutics--

LGND Revenue FAQ

What is Ligand Pharmaceuticals’s yearly revenue?

Ligand Pharmaceuticals's yearly revenue for 2023 was $131.31M, representing a decrease of -33.09% compared to 2022. The company's yearly revenue for 2022 was $196.24M, representing a decrease of -29.19% compared to 2021. LGND's yearly revenue for 2021 was $277.13M, representing an increase of 48.66% compared to 2020.

What is Ligand Pharmaceuticals’s quarterly revenue?

Ligand Pharmaceuticals's quarterly revenue for Q3 2024 was $51.81M, a 24.76% increase from the previous quarter (Q2 2024), and a 57.64% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $41.53M, a 34.07% increase from the previous quarter (Q1 2024), and a 57.52% increase year-over-year (Q2 2023). LGND's quarterly revenue for Q1 2024 was $30.98M, a 10.24% increase from the previous quarter (Q4 2023), and a -29.56% decrease year-over-year (Q1 2023).

What is Ligand Pharmaceuticals’s revenue growth rate?

Ligand Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -52.62%, and for the last 5 years (2019-2023) was 9.17%.

What are Ligand Pharmaceuticals’s revenue streams?

Ligand Pharmaceuticals's revenue streams in c 22 are Material Sales, Captisol, COVID, Material Sales, Captisol, License Fees, Milestones, and Other Product, Other, License Fees, Contract Revenue, Service, Royalty, Other, Royalty, Kyprolis, Royalty, Evomela, Royalty, Milestone, and Material Sales, Captisol, Core. Material Sales, Captisol, COVID generated $88.07M in revenue, accounting 23.94% of the company's total revenue Material Sales, Captisol generated $104.5M in revenue, accounting 28.40% of the company's total revenue, down -36.38% year-over-year. License Fees, Milestones, and Other Product, Other generated $6.11M in revenue, accounting 1.66% of the company's total revenue, down -4.76% year-over-year. License Fees generated $2.85M in revenue, accounting 0.77% of the company's total revenue, down -43.96% year-over-year. Contract Revenue generated $19.22M in revenue, accounting 5.22% of the company's total revenue, down -69.94% year-over-year. Service generated $1.12M in revenue, accounting 0.30% of the company's total revenue, down -95.29% year-over-year. Royalty, Other generated $7.63M in revenue, accounting 2.07% of the company's total revenue, down -32.90% year-over-year. Royalty, Kyprolis generated $30.12M in revenue, accounting 8.19% of the company's total revenue, up 9.62% year-over-year. Royalty, Evomela generated $10.2M in revenue, accounting 2.77% of the company's total revenue, up 1.17% year-over-year. Royalty generated $72.53M in revenue, accounting 19.71% of the company's total revenue, up 48.24% year-over-year. Milestone generated $9.15M in revenue, accounting 2.49% of the company's total revenue, down -68.17% year-over-year. Material Sales, Captisol, Core generated $16.43M in revenue, accounting 4.47% of the company's total revenue

What is Ligand Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Ligand Pharmaceuticals was Material Sales, Captisol. This segment made a revenue of $104.5M, representing 28.40% of the company's total revenue.